Depo-Provera and Meningioma Brain Tumors Lawsuit
The lawyers at Johnson//Becker, PLLC, are investigating injuries associated with Pfizer’s Depo-Provera. Depo-Provera was approved by the Food & Drug Administration (FDA) in 1992 as an injectable form of birth control. Rather than daily pills, women who use Depo-Provera receive a shot every three months. It is estimated that over 74 million women globally rely on this medication.
Recent findings have indicated a potential link between Depo-Provera and meningioma brain tumors. Meningiomas, though generally benign, can grow and impact brain function, causing symptoms like seizures, vision problems, and cognitive impairment, among others. Meningioma is treated with surgical removal and may include radiation and chemotherapy.
A French study from 2024 published in the British Medical Journal found a significantly higher risk of meningiomas for users of progestin drugs. Specifically, women who used medroxyprogesterone (the active ingredient in Depo-Provera) were found to be at least five times more likely to develop these tumors. The same study did not show an increased risk of meningiomas in women using oral contraceptives.